Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 107.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 148.50
  • 52 Week Low: 101.00
  • Currency: UK Pounds
  • Shares Issued: 106.69m
  • Volume: 0
  • Market Cap: £114.69m
  • RiskGrade: 190

Cello Health reports positive momentum as it works on US market

By Josh White

Date: Wednesday 18 Sep 2019

LONDON (ShareCast) - (Sharecast News) - Healthcare-focussed advisory firm Cello Health reported a 6.8% improvement in net revenue to £54.5m in its half-year results on Wednesday, with its like-for-like constant currency net revenue growth standing at 4.5%.
The AIM-traded company said Cello Health divisional net revenue growth was 11.6%, with like-for-like constant currency growth there being 8.2%.

Cello Signal divisional net revenue declined 0.1%, however, with like-for-like constant currency revenue in that division declining 1.0%.

The firm's headline profit before tax was ahead 12.7% year-on-year for the six months ended 30 June to £5.7m, while its headline operating margin improved to 10.9%, from 10.4% a year earlier.

Headline basic earnings per share were 12.7% higher at 4.08p, compared to 3.62p last year.

On a statutory basis, profit before tax was 39.7% higher at £4.7m, and basic earnings per share rose 40.3% to 3.31p.

The board reported "strong" cash flow for the period, with net funds as at 30 June standing at £2.2m, swinging from net debt of £5.4m a year prior.

It declared a 4.5% improvement to the interim dividend, to 1.15p.

On the operational front, Cello described "strong" growth across Cello Health, particularly in the United States, and added that its new Berlin office was now fully servicing European clients.

It added that the acquisition of ISS in August, post period end, further strengthened Cello Health's US advisory capability.

"The first half of 2019 has continued to see strong growth from Cello Health, notably in the US market," said chief executive officer Mark Scott.

"Cello Health Communications and Cello Health Consulting have made particularly pleasing progress."

Scott said the addition of ISS in August would help contribute to that momentum, and had added "critical" regulatory expertise.

"Good revenue visibility for the remainder of the year gives us confidence for a strong full year outcome."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 107.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 148.50
52 Week Low 101.00
Volume 0
Shares Issued 106.69m
Market Cap £114.69m
RiskGrade 190

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
37.27% below the market average37.27% below the market average37.27% below the market average37.27% below the market average37.27% below the market average
83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average
Price Trend
6.76% below the market average6.76% below the market average6.76% below the market average6.76% below the market average6.76% below the market average
45% below the sector average45% below the sector average45% below the sector average45% below the sector average45% below the sector average
Income
13.07% above the market average13.07% above the market average13.07% above the market average13.07% above the market average13.07% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
37.44% below the market average37.44% below the market average37.44% below the market average37.44% below the market average37.44% below the market average
11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  2nd Interim Interim
Ex-Div 23-Apr-20 03-Oct-19
Paid 22-May-20 01-Nov-19
Amount 1.00p 1.15p

Trades for --2020

Time Volume / Share Price
0 @ 0.000p

Cello Health Key Personnel

CEO Mark Scott

Top of Page